Sign up to this On-Demand webinar to review the new Olink® Signature Q100, a benchtop system for protein biomarker analysis.
You can pre-order Olink® Signature Q100, designed for readout of Olink Target 96 and Target 48 protein biomarker panels. These panels offer Proximity Extension Assay (PEA) technology coupled to a qPCR readout, combining the best of antibody- and DNA-based methodologies to provide unique, enabling tools for protein biomarker analysis. In addition you will also review a comparison of Olink Target 48 Cytokine panel performance against existing protein analysis systems on the market
"Signature Q100 System - Evolution of workhorse for protein expression"
Bill Hunt, M.S.
Director of Product Management at Fluidigm
"Side by side comparison of Olink to existing multiplexed analysis systems"
Jenny Rubin, PhD,
Development Engineer at Olink Proteomics
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.